Institution
Université de Sherbrooke
Education•Sherbrooke, Quebec, Canada•
About: Université de Sherbrooke is a education organization based out in Sherbrooke, Quebec, Canada. It is known for research contribution in the topics: Population & Receptor. The organization has 14922 authors who have published 28783 publications receiving 792511 citations. The organization is also known as: Universite de Sherbrooke & Sherbrooke University.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Overall, it is shown that averaging improves quality of tractography, sharp angular ODF profiles helps tractography and deterministic tractography produces less invalid tracts which leads to better connectivity results than probabilistic tractography.
211 citations
••
University College London1, University of Manchester2, University of Leicester3, Norwegian Institute of Public Health4, University of Aberdeen5, Sheba Medical Center6, Riley Hospital for Children7, Université de Sherbrooke8, Guangzhou Medical University9, Pontifícia Universidade Católica do Rio Grande do Sul10
TL;DR: These equations improve existing pediatric equations by considering the between-subject variability to define a more appropriate age-dependent lower limit of normal and provide a foundation that will facilitate continued updating.
Abstract: RATIONALE: Advances in spirometry measurement techniques have made it possible to obtain measurements in children as young as 3 years of age; however, in practice, application remains limited by the lack of appropriate reference data for young children, which are often based on limited population-specific samples. OBJECTIVES: We aimed to build on previous models by collating existing reference data in young children (aged 3-7 years), to produce updated prediction equations that span the preschool years and that are also linked to established reference equations for older children and adults. METHODS: The Asthma UK Collaborative initiative was established to collate lung function data from healthy young children aged 3-7 years. Collaborators included researchers with access to pulmonary function test data in healthy preschool children. Spirometry centiles were created using the LMS (Lambda-Mu-Sigma) method and extend previously published equations down to 3 years of age. MAIN RESULTS: The Asthma UK centiles charts for spirometry are based on the largest sample of healthy young Caucasian children aged 3-7 years (n=3777) from 15 centers across 11 countries and provide a continuous reference with a smooth transition into adolescence and adulthood. These equations improve existing pediatric equations by considering the between-subject variability to define a more appropriate age-dependent lower limit of normal. The collated dataset reflects a variety of equipment, measurement protocols and population characteristics and may be generalizable across different populations. CONCLUSIONS: We present prediction equations for spirometry for preschool children and provide a foundation which will facilitate continued updating.
211 citations
••
McMaster-Carr1, McMaster University2, McGill University Health Centre3, McGill University4, Dalhousie University5, Université de Sherbrooke6, University of Victoria7, University Medical Center Groningen8, University of British Columbia9, University of Manitoba10, St. John's University11, University of Ottawa12, University of Waterloo13, Simon Fraser University14
TL;DR: The final author version and the galley proof are versions of the publication after peer review that features the final layout of the paper including the volume, issue and page numbers.
Abstract: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers.
211 citations
••
University of California, Davis1, University of Notre Dame2, Brown University3, Australian National University4, Virginia Tech5, University of California, Irvine6, National Autonomous University of Mexico7, Defenders of Wildlife8, University of California, Berkeley9, University of Évora10, University of Minnesota11, United States Bureau of Reclamation12, University of Wisconsin-Madison13, United States Geological Survey14, United States Fish and Wildlife Service15, Conservation International16, New York University17, Arizona State University18, Lewis & Clark College19, Stellenbosch University20, Stanford University21, National Oceanic and Atmospheric Administration22, Université de Sherbrooke23, University of Nebraska–Lincoln24
TL;DR: In this article, an interdisciplinary team considered ethics, law, policy, ecology, and natural resources management in order to identify the key issues of managed relocation relevant for developing sound policies.
Abstract: Managed relocation is defined as the movement of species, populations, or genotypes to places outside the areas of their historical distributions to maintain biological diversity or ecosystem functioning with changing climate. It has been claimed that a major extinction event is under way and that climate change is increasing its severity. Projections indicating that climate change may drive substantial losses of biodiversity have compelled some scientists to suggest that traditional management strategies are insufficient. The managed relocation of species is a controversial management response to climate change. The published literature has emphasized biological concerns over difficult ethical, legal, and policy issues. Furthermore, ongoing managed relocation actions lack scientific and societal engagement. Our interdisciplinary team considered ethics, law, policy, ecology, and natural resources management in order to identify the key issues of managed relocation relevant for developing sound policies th...
211 citations
••
University of Toronto1, University of São Paulo2, King Saud University3, Medical College of Wisconsin4, University College Dublin5, Mater Misericordiae University Hospital6, Université de Sherbrooke7, Libin Cardiovascular Institute of Alberta8, Ottawa Hospital Research Institute9, Queen's University10, University of Vermont11, University of Vermont Medical Center12, Université de Montréal13, University of Alberta14, Radboud University Nijmegen15, University of British Columbia16, University of Bern17
TL;DR: In this paper, the authors evaluated the effects of therapeutic heparin compared with prophylactic hepharmin among moderately ill patients with covid-19 admitted to hospital wards.
Abstract: Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised controlled, adaptive, open label clinical trial. Setting 28 hospitals in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and US. Participants 465 adults admitted to hospital wards with covid-19 and increased D-dimer levels were recruited between 29 May 2020 and 12 April 2021 and were randomly assigned to therapeutic dose heparin (n=228) or prophylactic dose heparin (n=237). Interventions Therapeutic dose or prophylactic dose heparin (low molecular weight or unfractionated heparin), to be continued until hospital discharge, day 28, or death. Main outcome measures The primary outcome was a composite of death, invasive mechanical ventilation, non-invasive mechanical ventilation, or admission to an intensive care unit, assessed up to 28 days. The secondary outcomes included all cause death, the composite of all cause death or any mechanical ventilation, and venous thromboembolism. Safety outcomes included major bleeding. Outcomes were blindly adjudicated. Results The mean age of participants was 60 years; 264 (56.8%) were men and the mean body mass index was 30.3 kg/m2. At 28 days, the primary composite outcome had occurred in 37/228 patients (16.2%) assigned to therapeutic heparin and 52/237 (21.9%) assigned to prophylactic heparin (odds ratio 0.69, 95% confidence interval 0.43 to 1.10; P=0.12). Deaths occurred in four patients (1.8%) assigned to therapeutic heparin and 18 patients (7.6%) assigned to prophylactic heparin (0.22, 0.07 to 0.65; P=0.006). The composite of all cause death or any mechanical ventilation occurred in 23 patients (10.1%) assigned to therapeutic heparin and 38 (16.0%) assigned to prophylactic heparin (0.59, 0.34 to 1.02; P=0.06). Venous thromboembolism occurred in two patients (0.9%) assigned to therapeutic heparin and six (2.5%) assigned to prophylactic heparin (0.34, 0.07 to 1.71; P=0.19). Major bleeding occurred in two patients (0.9%) assigned to therapeutic heparin and four (1.7%) assigned to prophylactic heparin (0.52, 0.09 to 2.85; P=0.69). Conclusions In moderately ill patients with covid-19 and increased D-dimer levels admitted to hospital wards, therapeutic heparin was not significantly associated with a reduction in the primary outcome but the odds of death at 28 days was decreased. The risk of major bleeding appeared low in this trial. Trial registration ClinicalTrials.gov NCT04362085.
210 citations
Authors
Showing all 15051 results
Name | H-index | Papers | Citations |
---|---|---|---|
Masashi Yanagisawa | 130 | 524 | 83631 |
Joseph V. Bonventre | 126 | 596 | 61009 |
Jeffrey L. Benovic | 99 | 264 | 30041 |
Alessio Fasano | 96 | 478 | 34580 |
Graham Pawelec | 89 | 572 | 27373 |
Simon C. Robson | 88 | 552 | 29808 |
Paul B. Corkum | 88 | 576 | 37200 |
Mario Leclerc | 88 | 374 | 35961 |
Stephen M. Collins | 86 | 320 | 25646 |
Ed Harlow | 86 | 190 | 61008 |
William D. Fraser | 85 | 827 | 30155 |
Jean Cadet | 83 | 372 | 24000 |
Vincent Giguère | 82 | 227 | 27481 |
Robert Gurny | 81 | 396 | 28391 |
Jean-Michel Gaillard | 81 | 410 | 26780 |